Metabolomic profile of prostate cancer-specific survival among 1812 ... - BMC Medicine

-

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  • Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, et al. Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. J Natl Cancer Inst. 2021;113(6):727–34.

    Article  PubMed  Google Scholar 

  • Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv123.

    Article  Google Scholar 

  • Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem. 2004;91(3):553–71.

    Article  CAS  PubMed  Google Scholar 

  • Salciccia S, Capriotti AL, Lagana A, Fais S, Logozzi M, De Berardinis E, et al. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int J Mol Sci. 2021;22(9):4367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev. 2016;25(6):887–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nicholson G, Rantalainen M, Maher AD, Li JV, Malmodin D, Ahmadi KR, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol. 2011;7:525.

    Article  PubMed  PubMed Central  Google Scholar 

  • Playdon MC, Joshi AD, Tabung FK, Cheng S, Henglin M, Kim A, et al. Metabolomics Analytics Workflow for Epidemiological Research: Perspectives from the Consortium of Metabolomics Studies (COMETS). Metabolites. 2019;9(7):145.

    Article  CAS  PubMed Central  Google Scholar 

  • Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2011;40(1):387–426.

    Article  CAS  PubMed  Google Scholar 

  • Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer. 2015;137(9):2124–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rohnisch HE, Kyro C, Olsen A, Thysell E, Hallmans G, Moazzami AA. Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study. BMC Med. 2020;18(1):187.

    Article  PubMed  PubMed Central  Google Scholar 

  • Huang J, Mondul AM, Weinstein SJ, Koutros S, Derkach A, Karoly E, et al. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Br J Cancer. 2016;115(9):1087–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang J, Mondul AM, Weinstein SJ, Derkach A, Moore SC, Sampson JN, et al. Prospective serum metabolomic profiling of lethal prostate cancer. Int J Cancer. 2019;145(12):3231–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Med. 2017;15(1):122.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cerrato A, Bedia C, Capriotti AL, Cavaliere C, Gentile V, Maggi M, et al. Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine. Anal Chim Acta. 2021;1158:338381.

    Article  CAS  PubMed  Google Scholar 

  • Lima AR, Pinto J, Amaro F, Bastos ML, Carvalho M, Guedes de Pinho P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites. 2021;11(3):181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang J, Weinstein SJ, Moore SC, Derkach A, Hua X, Mondul AM, et al. Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival. J Gerontol A Biol Sci Med Sci. 2019;74(6):853–9.

    Article  CAS  PubMed  Google Scholar 

  • Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.

    Article  CAS  PubMed  Google Scholar 

  • Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge University Press; 1997.

    Book  Google Scholar 

  • Chen H, Lumley T, Brody J, Heard-Costa NL, Fox CS, Cupples LA, et al. Sequence kernel association test for survival traits. Genet Epidemiol. 2014;38(3):191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, et al. Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr. 2012;96(4):855–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guertin KA, Li XS, Graubard BI, Albanes D, Weinstein SJ, Goedert JJ, et al. Serum Trimethylamine N-oxide, Carnitine, Choline, and Betaine in Relation to Colorectal Cancer Risk in the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev. 2017;26(6):945–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012;18(21):5888–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fazzari J, Lin H, Murphy C, Ungard R, Singh G. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015;5:8380.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593–602.

    Article  CAS  PubMed  Google Scholar 

  • Nilsson A, Haanstra JR, Engqvist M, Gerding A, Bakker BM, Klingmuller U, et al. Quantitative analysis of amino acid metabolism in liver cancer links glutamate excretion to nucleotide synthesis. Proc Natl Acad Sci U S A. 2020;117(19):10294–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martin L, Gardner LB. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11. Oncogene. 2015;34(32):4211–8.

    Article  CAS  PubMed  Google Scholar 

  • Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, et al. Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer. Br J Cancer. 2013;109(3):610–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bansal A, Sanchez DJ, Nimgaonkar V, Sanchez D, Riscal R, Skuli N, et al. Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression. Mol Cancer Res. 2019;17(9):1881–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of prostate cancer: Findings from the KIHD prospective cohort study. Int J Cancer. 2017;140(4):818–24.

    Article  CAS  PubMed  Google Scholar 

  • Laezza C, Pagano C, Navarra G, Pastorino O, Proto MC, Fiore D, et al. The Endocannabinoid System: a target for cancer treatment. Int J Mol Sci. 2020;21(3):747. https://doi.org/10.3390/ijms21030747.

    Article  CAS  PubMed Central  Google Scholar 

  • Diaz-Laviada I. The endocannabinoid system in prostate cancer. Nat Rev Urol. 2011;8(10):553–61.

    Article  CAS  PubMed  Google Scholar 

  • Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of Amino Acids in Cancer. Front Cell Dev Biol. 2020;8:603837.

    Article  PubMed  Google Scholar 

  • Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol. 2020;17(4):214–31.

    Article  PubMed  Google Scholar 

  • Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR. The ins and outs of serine and glycine metabolism in cancer. Nat Metab. 2021;3(2):131–41.

    Article  PubMed  Google Scholar 

  • Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Panagiotopoulos AA, Kalyvianaki K, Castanas E, Kampa M. Eicosanoids in prostate cancer. Cancer Metastasis Rev. 2018;37(2-3):237–43.

    Article  CAS  PubMed  Google Scholar 

  • Separovic D, Shields AF, Philip PA, Bielawski J, Bielawska A, Pierce JS, et al. Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. Anticancer Res. 2017;37(3):1213–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang Y, Tie C, Wang Y, Bian D, Liu M, Wang T, et al. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. Front Oncol. 2020;10:1759.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.

    Article  CAS  PubMed  Google Scholar 

  • Kroll A, Cho HE, Kang MH. Antineoplastic Agents Targeting Sphingolipid Pathways. Front Oncol. 2020;10:833.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wanders D, Hobson K, Ji X. Methionine Restriction and Cancer Biology. Nutrients. 2020;12:3.

    Article  Google Scholar 

  • Lu WC, Saha A, Yan W, Garrison K, Lamb C, Pandey R, et al. Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proc Natl Acad Sci U S A. 2020;117(23):13000–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene. 2016;35(38):4957–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen CL, Hsu SC, Ann DK, Yen Y, Kung HJ. Arginine Signaling and Cancer Metabolism. Cancers (Basel). 2021;13:14.

    Google Scholar 

  • Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A. Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia. 2009;11(7):692–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 2001;22(11):1765–73.

    Article  CAS  PubMed  Google Scholar 

  • Hada M, Edin ML, Hartge P, Lih FB, Wentzensen N, Zeldin DC, et al. Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2019;28(1):189–97.

    Article  PubMed  Google Scholar 

  • He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wu Q, Xie X, Huang Y, Meng S, Li Y, Wang H, et al. N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer. J Cancer. 2021;12(3):682–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ji G, Huang C, He S, Gong Y, Song G, Li X, et al. Comprehensive analysis of m6A regulators prognostic value in prostate cancer. Aging (Albany NY). 2020;12(14):14863–84.

    Article  CAS  Google Scholar 

    • Comments

    Post a Comment

    Popular posts from this blog

    Sentinel lymph node biopsy: What cancer patients should know

    -
    Image
    cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
    Read more

    Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

    -
    Image
    Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with  BRCA1/2  or  ATM  alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the  BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or  RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...
    Read more

    Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer - RSNA Publications Online

    -
    Image
    Abstract In patients with prostate cancer, prostate MRI can be used to detect and diagnose disease, identify dominant intraprostatic lesions that may be treated with a higher radiation dose, help segment radiation treatment targets, and evaluate fiducial marker and hydrogel spacer placements for radiation treatment planning and delivery. Prostate MRI is increasingly being used to make diagnoses and guide management for patients receiving definitive radiation treatment for prostate cancer. Radiologists should be familiar with the potential uses of prostate MRI in radiation therapy planning and delivery. Radiation therapy is an established option for the definitive treatment of localized prostate cancer. Stereotactic body radiation therapy (SBRT) is an external-beam radiation therapy method used to deliver a high dose of radiation to an extracranial target in the body, often in five or fewer fractions. SBRT is increasingly being used for prostate cancer treatment and has been recognized ...
    Read more